Tag Archives: apple

Why I Sold Berkshire Hathaway And Added Quality To My Portfolio

Summary Berkshire Hathaway may be a model for a quality company and merits a place in one’s portfolio on that basis. Berkshire Hathaway’s recent performance has been disappointing. Can an ETF focused on the quality factor replace it and improve returns as well as portfolio quality? I continue to review my holdings with an eye to what I want to keep and what’s not earning its keep. After a hard look, I decided Berkshire Hathaway (NYSE: BRK.B ) just wasn’t getting it done. Take a look at some stats for BRK.B and the ETFs tracking the S&P 500 and the NASDAQ 100. Annualized Volatility Beta Daily Value at Risk Max Drawdown Total Return (1 year) BRK.B 14.2% 0.91 2.1% -6.3% 4.4% SPDR S&P 500 Trust ETF ( SPY) 12.7% 1.00 1.9% -4.9% 9.5% PowerShares QQQ Trust ETF ( QQQ) 13.7% 0.99 2.0% -5.7% 11.8% Looking at these numbers, I asked myself “Why?” Why do I need something that I think of as high-quality but ultraconservative yet has greater volatility than the NASDAQ 100. And with that volatility comes barely a third QQQ’s return. It has greater volatility than the S&P 500 as well, and half of SPY’s return. Sure, the stock has had great years in the past, but when I ask what it’s done for me lately, I’m not getting an answer that tells me to hold onto it, especially since it’s a large holding for me. The question was, what do I replace it with? In looking for the answer, I asked myself why I was holding BRK.B. What came immediately to mind? Quality. When I bought the stock it was because I viewed it as the model for quality. So, while I was deciding to part ways with BRK, I had to decide how to fill the gap it would leave. I might have begun by considering other stocks, of course. But, another factor that entered into my thinking is that I have been moving away from individual stock holdings in favor of funds. That decision is the subject of another discussion altogether, but especially for places where a stock is occupying a structural role in my portfolio, I think it can make more sense to fill that slot with an ETF that does the same job. So, what I wanted was a fund that emphasized high-quality. What Asness et al., following the Fama-French factor terminology, called Quality Minus Junk in their 2013 paper on the subject. In that paper they define quality stocks as being “safe, profitable, growing, and well managed” and showed how the quality factor has outperformed. After BRK.B had a nice pop on Thursday and Friday, I decided it was time. I could have gone with one of AQR’s mutual funds, which are built on Asness’s rigorous research. But, even if the door was open to me, I’m not in a position to fork out the cost of entry. These funds have a nominal minimum purchase of $1-5 Million depending on share type. I have a large holding in BRK.B but not remotely that large. In addition there are fees that approach 2%, and the funds are generally available only through advisors. I’m sure you can get in for less than that nominal seven-figure requirement if your timing and brokerage are right. In fact I do hold an AQR mutual fund purchased this way despite its nominal $1M minimum. But most of them are closed to new or even current investors. A smart move by the funds’ management, keeping the funds something halfway between an open-end and closed-end mutual fund. I won’t argue the desirability of AQR mutual funds, but as I go through them, I don’t see enough to justify those barriers to me. What I went for was the iShares MSCI USA Quality Factor ETF (NYSEARCA: QUAL ), which does what it says on the label: Emphasizes the quality factor. QUAL: Top Ten Holdings and Sector Distribution When I start to look at an ETF almost the first thing I do is look at the portfolio. (click to enlarge) I found that the top six positions in QUAL were also in my own portfolio: Microsoft (NASDAQ: MSFT ), Johnson & Johnson (NYSE: JNJ ), Apple (NASDAQ: AAPL ), Gilead (NASDAQ: GILD ), Berkshire Hathaway and Costco (NASDAQ: COST ). Four more of my stocks were in the top 20: Celgene (NASDAQ: CELG ), AT&T (NYSE: T ), Chevron (NYSE: CVX ) and Qualcom (NASDAQ: QCOM ). I hold a total of 14 individual stocks, and I look primarily for quality in my choices. So, I was struck by the convergence of my opinion and that of QUAL’s passive algorithm. I’m not sure I’ve ever looked at an ETF portfolio and found 70% of my portfolio’s stocks in the ETF’s top 20. And I’m certain I’ve never hit all of the first 6. I felt the algorithm validated decisions I’ve made over a period of several years, and this fund was a fit for my own approach to investing. Sector weighting also aligned with my own portfolio strategies. (click to enlarge) I have a modest allocation to a dual-momentum sector-switching strategy. For the past year and a half or so it’s been in information tech, healthcare, consumer discretionary most of the time it hasn’t been in the out-of-market position. The QUAL index has loaded the portfolio with 70% allocation to those sectors. Again, I felt I was moving along the same path. So, with the validation that my investment strategies and QUAL’s index algorithm were generating similar choices, it seemed clear that I had to look more closely. QUAL’s Strategy and Implementation Quality can be a nebulous concept. The most important question was: How does the fund define quality? According to the fund’s factsheet they use “three fundamental variables: high return on equity, stable year-over-year earnings growth and low financial leverage.” Not unreasonable indicators of Asness’s “safe, profitable, growing, and well managed” definition of quality. The MSCI index description expands this with the quantitative details: A quality score… is calculated by combining Z scores of three winsorized fundamental variables-Return on Equity, Debt to Equity and Earnings Variability. MSCI then averages the Z scores of each of the three fundamental variables to calculate a composite quality Z score… then ranks all constituents of the parent index based on their quality scores. Weighting is determined by the product of market cap weight in the index and quality score. Weights are capped at 5%. As an aside to stock-pickers, think about how high MSFT and JNJ must score on the quality scale to overcome AAPL’s market cap advantage in rising above it in the weighting here. It’s an approach that should lead to emphases on both fundamental value and momentum. I liked what I saw, and feel most would agree that these indicators do indeed reflect a concept of a quality company. They are clearly necessary components of quality, although perhaps not sufficient. I’m sure all of us could add metrics we’d like to see included. But I was satisfied with it at this level. QUAL’s History The fund has 27 months of history (July 16, 2013) and net assets of $1.2B. The total portfolio is set at 125 holdings. SEC 30-day yield as of September 30 is 1.94%. Its beta is 0.92. And its fee is only 0.15%. Returns since the fund’s inception are about a third better than SPY and twice what BRK.B has turned in. (click to enlarge) For longer term evaluation we have to go to the index. It’s always problematic to base decisions on a fund using the historical performance of its index, but it’s what we have. Here we have MSCI’s 15 year chart of the index vs. its USA index of domestic stocks. (click to enlarge) Morningstar’s Samuel Lee looked at the fund and its index about a month after it was introduced ( here ). He called it a “Buffett in a Box,” and ran up this analysis where he divides the MSCI Quality Index by the MSCI USA Index. On this chart positive numbers represent outperformance of the quality index relative to the domestic market index. For the 30 years prior to QUAL’s inception the index outperformed by 60%. What you really want to see in this chart, however, is the changes in slope because the positive slopes represent periods of QUAL’s outperfomance. During bull markets, quality lags, but during downturns it shows its breeding. (click to enlarge) Lee compared QUAL to the Vanguard Dividend Appreciation ETF (NYSEARCA: VIG ) noting the he’ll be watching it in comparison to VIG with an eye toward moving his VIG position to QUAL if the fund evolved as he anticipated it should. Here’s what he would have seen when he followed through: (click to enlarge) Trading for Quality So, near the close on Friday I sold my entire position in BRK.B and put the proceeds into QUAL. I started my project to replace individual stocks with funds by focusing on BRK.B for two reasons. First, it has been turning in disappointing returns recently, and second I have a large allocation to the stock, larger than I feel appropriate. There are two other stocks I’m holding at much lower allocations that I have been looking to trade out of as well: JNJ and T. I like having both of them for the same reasons I like BRK.B: stability and quality. But, like BRK.B there underperformance comes with opportunity costs. How do those opportunity costs stack up against what QUAL has been returning? (click to enlarge) What this is telling me is that I can jack up my returns with little, if any, sacrifice in portfolio quality by moving these allocations to QUAL as well. The biggest problem I have with QUAL is one of the things that attracted me to it in the first place. That is the extent to which it duplicates what I’m already holding. I’m not prepared to trade out of GILD, COST or CELG at this time. I think each of those has excellent prospects to outperform the market and their sectors. I also hold a large (my largest, in fact) position in AAPL that I’d like to cut back. I’ll probably do so after earnings this week if, as I expect, we get another positive report. But my other duplications I’m more ambivalent about. I like MSFT and it is certainly not underperforming (75% total return vs. QUAL’s 33.5% on the scale of the above charts) but if I had a quality substitute, I would not miss it. The other I replicate is CVX where I’m underwater but am willing to wait for the oil cycle to turn before I do anything there. Of course, most funds I own replicate some part of my portfolio, especially with AAPL and GILD among the top holdings of nearly every fund I find interesting. Bottom line on this exercise for me: I like QUAL, perhaps as much as any ETF I’ve looked at recently. For my purposes, it can serve the same role in my portfolio as individual stocks of quality that have been, and likely will continue to be, underperforming the market.

ALFA Underwhelms As Hedge Fund Darlings Crater Plus An Untimely Hedge

Summary ALFA’s hedge was triggered for the first time at the start of last September. Unfortunately, ALFA’s recent performance has been uninspiring. This analysis reveals two likely reasons for ALFA’s underperformance since the hedge was activated. In my Aug. 31, 2015 article entitled ” ALFA: A Market-Beating ETF About To Go Market-Neutral ” I reported that the AlphaClone Alternative Alpha ETF (NYSEARCA: ALFA ) was about to go market-neutral for the first time since its inception due to the S&P 500 closing below its 200-day moving average at month-end. I also commented on the fact that ALFA has had significant wire-to-wire outperformance vis-a-vis the SPDR S&P 500 Trust ETF ( SPY) since inception (see chart below), suggesting that investors in ALFA benefited from being able to “invest with the best.” Recall that ALFA uses a proprietary “Clone Score” methodology in order to aggregate the ideas of hedge funds which have strong historical performance. Alas, ALFA can no longer lay claim to this achievement. Its total return performance since inception now trails SPY by some 15% (55% vs. 70%). ALFA Total Return Price data by YCharts Zooming up to the time frame since the hedge was triggered at the start of September (it was actually activated at the market close on Sep. 2nd) reveals that most of the relative underperformance occurred over the last month. ALFA Total Return Price data by YCharts Reconstructing ALFA’s return without the hedge Recall that when the hedge is triggered (caused by the S&P 500 closing below its 200-day moving average at month-end), ALFA shorts the S&P 500 in an amount equal to the notional value of its long holdings. In other words, ALFA becomes market-neutral. Obviously, given that SPY has (as of last week) reclaimed its 200-day moving average in a brief span of two months, the hedge appears to be ill-timed. Nevertheless, investors in ALFA must be prepared to accept the fact that this hedging strategy will likely underperform in whipsaw situations, such as what was observed over the past two months, as part of the cost of protecting oneself from the worst of bear markets. I wanted to see whether the severe underperformance of ALFA was due to the hedge being triggered, or something else. Therefore, I reconstructed the total return of ALFA since the start of September to visualize what the return profile of ALFA would have been if the hedge had not been activated. We can see from the chart above that had the hedge not been activated, the hypothetical 100% long ALFA (denoted ALFA-L in the graph above) would have returned -1.95% since Sep. 1st, compared to -8.14% for the actual ALFA. While this alleviates the underperformance a bit, it is still far below that of SPY at 8.69%. So what can the rest of ALFA’s underperformance be attributed to? Hedge fund darlings crater In my previous article, I compared the top 10 holdings of ALFA and SPY. ALFA SPY Stock Ticker % Assets Stock Ticker % Assets Apple Inc. (NASDAQ: AAPL ) 7.25 Apple Inc. AAPL 3.75 Valeant Pharmaceuticals (NYSE: VRX ) 7.19 Microsoft Corporation (NASDAQ: MSFT ) 2.03 Celgene Corporation (NASDAQ: CELG ) 2.55 Exxon Mobil Corporation Common (NYSE: XOM ) 1.78 Horizon Pharma plc (NASDAQ: HZNP ) 2.53 Johnson & Johnson Common Stock (NYSE: JNJ ) 1.49 Allergan PLC (NYSE: AGN ) 2.41 Wells Fargo & Company Common St (NYSE: WFC ) 1.46 The Priceline Group Inc. (NASDAQ: PCLN ) 2.36 General Electric Company Common (NYSE: GE ) 1.41 Transdigm Group Incorporated Tr (NYSE: TDG ) 2.22 Berkshire Hathaway Inc. Class B (NYSE: BRK.B ) 1.4 Oracle Corporation Common Stock (NYSE: ORCL ) 2.05 JPMorgan Chase & Co. Common St (NYSE: JPM ) 1.37 Biogen Idec Inc. (NASDAQ: BIIB ) 1.79 Pfizer, Inc. Common Stock (NYSE: PFE ) 1.19 Skechers U.S.A., Inc. Common St (NYSE: SKX ) 1.5 AT&T Inc. (NYSE: T ) 1.15 How have the top 10 stocks of ALFA fared over the past two months? Answer: not pretty. AAPL Total Return Price data by YCharts As can be seen from the graph above, only 2 of ALFA’s top 10 holdings at the start of September, PCLN (+12.44%) and AAPL (+10.55%), have outperformed SPY. There are three massive losers: SKX (-30.5%), HZNP (-41.2%) and VRX (-48.2%). Assuming that the weightings of those three stocks did not change over this time period, they would have contributed a total of -6.24% to the total return of ALFA over this time period. That actually accounts for over half the entire difference between the hypothetical unhedged ALFA-L (-1.95%) and SPY (8.69%) during this time! Now, I am aware that ALFA’s holdings are not static, and hence the above calculation is merely an estimate. Nevertheless, it is clear that ALFA has been hit by a “doubly-whammy” of an untimely hedge, plus the underperformance of hedge fund darlings such as Valeant Pharmaceuticals (see this comically-timed Forbes article ” Hedge Fund Superstars Stocking Up On Valeant Pharmaceuticals ” that was published the day before VRX’s price came crashing down). This illustrates an important fact: even the best and brightest in the industry can sometimes get it (very) wrong. Due to ALFA’s heavy concentration in tech and biotech, one might say that SPY is not an appropriate benchmark for ALFA. The following chart therefore also shows the total return of the PowerShares QQQ Trust ETF (NASDAQ: QQQ ) and the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) since the start of September, as well that of another hedge fund-following ETF, the Global X Guru Index ETF (NYSEARCA: GURU ). Unfortunately, ALFA still lags the other four ETFs, although the hypothetical ALFA-L (-1.95%) would have outperformed IBB (-5.12%) and closely trail GURU (-0.37%). ALFA Total Return Price data by YCharts Summary The last two months has not been kind to ALFA holders. Not only was the timing of the hedge unfortunate, but a number of the fund’s largest holdings have suffered tremendously, particularly VRX and HZNP, whose pricing practices have come under intense scrutiny. Will ALFA rebound in the future? I don’t know. As of today, VRX and HZNP are still two of ALFA’s top 10 holdings, at 3.30% and 2.00% weights, respectively, suggesting that ALFA’s future performance may still be somewhat tethered to the fates of those two specialty pharmaceutical companies. Moreover, note that while ALFA is currently in market-neutral mode, this will change if the S&P 500 manages to remain above its 200-day moving average for one more week, as the end of the month is near.

Apple Chip Suppliers Plunge On Shaky Dialog Q4 View

Apple (AAPL) chip suppliers tumbled Monday on Wall Street after a German iPhone 6S chip supplier guided Q4 revenue growth down to single digits, a day before Apple is expected to report colossal earnings. Dialog Semiconductor’s 20% dip in shares could also hurt its $4.6 billion attempt to acquire Silicon Valley chip gear maker Atmel (ATML). In September, Dialog valued Atmel at $10.42 per share. Now, the deal is worth 20% less. In early trading,